SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Will Brexit lead to fewer NHS physicians and more medical tourism? With greater independence comes a health care conundrum

UTA and UT Southwestern partner for heavy ion therapy and better IGRT Redefining what's possible with radiation

Shows and Events – FIME under new management FIME set to welcome attendees in Miami Beach

Stryker recalls its angiographic catheter due to tip separation Labeled as Class I recall, the catheters should be returned to manufacturer

U.S. government blocks historic health insurance mega-mergers Anthem-Cigna and Aetna-Humana deals deemed bad for competition

Imaging facilities can survive cuts to Medicare reimbursements Benefits of DR technology must be recognized

Superconducting MR coil points to faster, better patient scan times Preclinical research shows dramatic improvements in signal-to-noise ratio

Florida trio accused of unprecedented $1 billion Medicare fraud Largest U.S. health care fraud case ever brought against individuals

Dense breasts? Depends on who you ask, say researchers Digital mammo and automated methods expected to curb variation

Enrollment in Alzheimer's clinical trials remains low despite willingness to get involved What can be done to improve participation?

Amyloid imaging lights up SNM 2012

by Loren Bonner , DOTmed News Online Editor
Presenters at the 59th annual SNM meeting in Miami Beach, Fla., unveiled an array of breakthrough research and new techniques to detect evidence of Alzheimer's in living patients -- including, possibly, in asymptomatic populations.

Researchers know that beta-amyloid plaque can build up in the brain several years before an individual shows any signs of dementia. And many scientists believe that this plaque can kill vital neural pathways that are responsible for language, memory and behavior.

Story Continues Below Advertisement

Looking for locating technology but can't decide on a direction?

Whether you want to use existing Wi-Fi to track assets enterprise-wide, automate par-level asset management or leverage your investment for patient & staff workflow...Versus will put you on the path to RTLS success. Visit us at AAMI Booth # 930



"Molecular imaging can detect signs of Alzheimer's disease many years before patients develop dementia. It can do this because it can target beta-amyloid," says Dr. Christopher Rowe, a lead investigator for the Australian Imaging, Biomarkers and Lifestyle study of aging and professor of nuclear medicine at Austin Hospital in Melbourne, Australia.

In one of the studies presented by Rowe's team, PET was combined with an F-18 imaging agent. Subjects who showed high levels of the tracer during imaging had an 80 percent chance of developing Alzheimer's within two years, according to study findings.

Research also found that beta-amyloid plaque in the brain was not only involved in the pathology of Alzheimer's disease but also preceded mild cognitive function.

"For those with mild memory problems who had a positive scan, 66 percent of these people progressed to dementia over three years. This compares to only 7 percent of those with a negative scan," says Rowe.

Rowe highlighted findings on this study at the meeting, which included 194 healthy elderly subjects, 92 subjects with mild cognitive impairment, and 70 subjects with Alzheimer's. C-11 Pittsburgh compound B (PiB) combined with PET was used to gauge amyloid burden in the brain.

"This is an opportunity to find the patient who has Alzheimer's and intervene with treatments as they become available," says Rowe.

He pointed out that being able to correctly identify which patients have Alzheimer's and which don't is a necessary stepping stone for developing potential drugs and therapies to treat the disease.

Alzheimer's can only be detected in a patient after death-- by studying postmortem brain samples with beta-amyloid plaque.

Currently, no reliable treatment exists for Alzheimer's patients and the screening tests that do exist are unreliable and limited in their ability to identify the disease early.

New biomarkers emerge

Any PET amyloid imaging test must begin with a biomarker. This year's SNM meeting presented some promising amyloid imaging agents in development that will help clinicians detect Alzheimer's in living patients.
  Pages: 1 - 2 - 3 >>

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2016 DOTmed.com, Inc.
ALL RIGHTS RESERVED